Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial.
Sivaprasad S, Arden G, Prevost AT, Crosby-Nwaobi R, Holmes H, Kelly J, Murphy C, Rubin G, Vasconcelos J, Hykin P. Sivaprasad S, et al. Among authors: prevost at. Trials. 2014 Nov 22;15:458. doi: 10.1186/1745-6215-15-458. Trials. 2014. PMID: 25417120 Free PMC article. Clinical Trial.
Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.
Sivaprasad S, Prevost AT, Bainbridge J, Edwards RT, Hopkins D, Kelly J, Luthert P, Murphy C, Ramu J, Sarafraz-Shekary N, Vasconcelos J, White-Alao B, Hykin P. Sivaprasad S, et al. Among authors: prevost at. BMJ Open. 2015 Sep 14;5(9):e008405. doi: 10.1136/bmjopen-2015-008405. BMJ Open. 2015. PMID: 26369798 Free PMC article. Clinical Trial.
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, Bainbridge J, Tudor-Edwards R, Hopkins D, Hykin P; CLARITY Study Group. Sivaprasad S, et al. Among authors: prevost at. Lancet. 2017 Jun 3;389(10085):2193-2203. doi: 10.1016/S0140-6736(17)31193-5. Epub 2017 May 7. Lancet. 2017. PMID: 28494920 Free article. Clinical Trial.
Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial.
Sivaprasad S, Vasconcelos JC, Prevost AT, Holmes H, Hykin P, George S, Murphy C, Kelly J, Arden GB; CLEOPATRA Study Group. Sivaprasad S, et al. Among authors: prevost at. Lancet Diabetes Endocrinol. 2018 May;6(5):382-391. doi: 10.1016/S2213-8587(18)30036-6. Epub 2018 Mar 5. Lancet Diabetes Endocrinol. 2018. PMID: 29519744 Free PMC article. Clinical Trial.
Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT.
Sivaprasad S, Hykin P, Prevost AT, Vasconcelos J, Riddell A, Ramu J, Murphy C, Kelly J, Edwards RT, Yeo ST, Bainbridge J, Hopkins D, White-Alao B. Sivaprasad S, et al. Among authors: prevost at. Southampton (UK): NIHR Journals Library; 2018 Oct. Southampton (UK): NIHR Journals Library; 2018 Oct. PMID: 30303670 Free Books & Documents. Review.
Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy.
Nicholson L, Crosby-Nwaobi R, Vasconcelos JC, Prevost AT, Ramu J, Riddell A, Bainbridge JW, Hykin PG, Sivaprasad S. Nicholson L, et al. Among authors: prevost at. Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4277-4284. doi: 10.1167/iovs.17-23509. Invest Ophthalmol Vis Sci. 2018. PMID: 30372756 Free PMC article. Clinical Trial.
190 results